BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9th at 10:30 a.m. at the InterContinental Boston.
Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions.
About Pear Therapeutics
At Pear, our mission is clear: we
are pioneers in Prescription Digital Therapeutics, or PDTs. Our
cross-functional team operates at the intersection of biotechnology
and software technology. Pear discovers, develops, and delivers
clinically-validated software-based therapeutics to provide better
outcomes for patients, smarter engagement and tracking tools for
clinicians, and cost-effective solutions for payers. Every day, we push
the boundaries of technology to transform medicine. Pear has a pipeline
of products and product candidates across therapeutic areas,
including mental health disorders, severe insomnia
and multiple sclerosis. Our lead product, reSET®, treats Substance
Use Disorder, and was the first PDT to receive marketing authorization
from the FDA to treat disease. Pear’s second product
candidate, reSET-O™ for the treatment of Opioid Use Disorder, is
currently under review by the FDA with Breakthrough Designation. For
more information, visit us at www.peartherapeutics.com.
